BMJ Open publishes all reviews undertaken for accepted manuscripts. Reviewers are asked to complete a checklist review form (http://bmjopen.bmj.com/site/about/resources/checklist.pdf) and are provided with free text boxes to elaborate on their assessment. These free text comments are reproduced below.
Introduction should be focused and pertain to the subject of the research. Right now there are lot of generalities about hypertension epidemiology and this needs to be trimmed.
Population of Mexico is mentioned as 8,851 million which should be 8.851 million I guess.
Since the screening for hypertension is being done once in two years, study design of time to event analysis may not be the right methodology. Please clarify.
Why has left arm been chosen for blood pressure measurement? Average of 3 bp measurements is being taken as the recorded BP. What if one of the recordings is very much different from other readings? Will it be repeated?
The standard bp measurement instrument across most studies is automatic oscillometric apparatus. However, the authors have chosen to use mercury sphygmomanometer. Given the concerns of environmental pollution due to mercury and that it is banned in several countries the authors may face problem with instrumentation especially in view of the long duration of study.
Please clarify what you mean by "Cardiac and respiratory frequencies will also be measured."
Details of how height, weight and abdominal circumference will be measured including instruments to be used should be provided. 
REVIEWER

GENERAL COMMENTS
This is a well written prospective study. I have just one very minor question. What incentives are planned for the participants in this study? Given that this is a longitudinal study the participants need some type of incentive to remain in the study. Incentives do not necessarily have to be monetary, but whatever they are, they should be stated in this paper.
VERSION 1 -AUTHOR RESPONSE
Reviewer 1
The authors intent to study factors leading to hypertension onset is very relevant, given the paucity of data in this area especially from developing countries. This would provide insights into managing this growing public health problem.
I have some major and minor comments as below:
The limitations should mention that macro levels factors like air pollution, migration, health system factors etc are not assessed in this study and these can impact incidence of outcome being studied.
-Answer: Agree. It was mentioned in the ´Strengths and limitations of this study" section, page 3, lines 62 and 63. It reads as follows: "Macro-level factors such as air pollution, migration and health system will not be assessed in this study, and these may impact incidence of HTN".
Certain grammatical errors need correction like in this sentence "Genetics has also been recognized as an important contributor for HTN predisposition, though it is until recently that genetic variants associated with HTN have been identified in different populations" -Answer: OK. Grammatical errors were corrected along the entire manuscript.
Use the term hypertensive heart diseases instead of hypertensive cardiopathy.
-Answer: Done. The term "hypertensive cardiopathy" was changed to "hypertensive heart diseases" in page 3, line 69.
-Answer: Done. Introduction has been modified to better reflect the aim of the study and generalities of HTN epidemiology were trimmed.
-Answer: Yes, the correct number is 8.851. It was corrected in the manuscript, page 4, line 97.
-Answer: We appreciate your comment and understand your concern in this regard. Indeed, screening for HTN will occur in person every two years as per protocol, and for those participants diagnosed with HTN during one of this biannual follow-up visits, the date of disease onset will be recorded as the date of the visit. However, in page 7, lines 155-164, it is also stated that: "All participants will be asked to immediately notify the investigators should they be diagnosed with HTN at another facility at any time during the life of the study. These participants will be asked to schedule a visit at the INCICh prior to starting any medical treatment to confirm the diagnosis and to complete the "end of the study' visit. The date of disease onset will be considered as the date of confirmation of the diagnosis. For those participants presenting a hypertensive crisis between follow-up visits requiring immediate treatment, the HTN diagnosis will be confirmed by medical records and then they will be scheduled for a clinical visit at the INCICh to complete the "end of study" visit. The day of the hypertensive crises will be considered the date of disease onset". Since this may occur at any time during the 10 years and the date of diagnosis will be established as one point in this time frame instead of being assigned to an interval of time (2 years), we consider that we will not have interval-censored data and would rather stick to the time-to-event analysis as planned.
Why has left arm been chosen for blood pressure measurement? -Answer: Differences in blood pressure measurements between arms are common and the precise etiology of this difference has not been clearly established (DOI: 10.2174/1381612820666141024124349). Due to a significant (>10 mmHg) SBP inter-arm difference is associated with increased CV risk, current hypertension guidelines (National Institute for Health and Clinical Excellence 2011 Clinical Guidelines, 2013 ESH/ESC Guidelines for the management of arterial hypertension) have suggested to check blood pressure in both arms and use the arm with the higher BP values; however, this is not a standardized procedure yet (DOI: 10.2174/1381612820666141024124349). In epidemiological studies, such as the present one, the affluence of participants is often quite high and the feasibility of measuring blood pressure in both arms is limited. Therefore, and in the light of similar prevalences of higher values for SBP and DBP in the right and left arm observed in young healthy subjects (DOI: 10.1111/jch.12125 and elderly) and in hospitalized elderly patients (DOI: 10.1111/jch.12345), we have decided to measure blood pressure in just one arm, the left one, since it is indistinctive (DOI:10.1097/HJH.0000000000001197) and more convenient due to practical aspects.
Average of 3 bp measurements is being taken as the recorded BP. What if one of the recordings is very much different from other readings? Will it be repeated? -Answer: Current guidelines recommend to take at least two blood pressure measurements (2013 ESH/ESC Guidelines for the management of arterial hypertension, JNC 7). We decided to take three and if one of these is quite different, we take another one and average the three closer values. It was clarified in page 8, lines 182-184: "Blood pressure will be measured in the left arm three times with a three-minute interval between each measurement, with the patient remaining in a sitting position for at least 10 minutes before the first evaluation. If one of the three measurements is quite different, another measure will be taken. The blood pressure value recorded will be the average of the three closer measurements".
-Answer: As the reviewer commented, automatic oscillometric devices are being increasingly used instead of mercury sphygmomanometer, mainly because of environmental concerns (Minamata Convention on Mercury, http://www.mercuryconvention.org/Portals/11/documents/Booklets/Minamata%20Convention%20on% 20Mercury_booklet_English.pdf). In the Annex A (p. 46-48, same link above) of Minamata Convention booklet, it is pointed out that a series of Mercury-added products are excluded of the prohibitions described in the document if they are being used for different purposes, among which research is mentioned.
Regarding our national legislations, the Official Mexican Standard for the prevention, treatment, and control of hypertension (NOM-030-SSA2-1999, http://www.salud.gob.mx/unidades/cdi/nom/030ssa29.html) points out that a mercury sphygmomanometer is preferably used to measure blood pressure. In addition, an important factor we considered was the superior accuracy of mercury sphygmomanometer compared with oscillometric devices, as several authors have questioned the accuracy of the latter Taking into account that import and export of devices containing mercury shall not be allowed after 2020 (with some exceptions), and Mexico is a signatory of the Minamata Convention, we are covered for such situation because a sufficient number of sphygmomanometers was exclusively assigned for this project. Additionally, our institution has a group of experts in the maintenance and calibration of these instruments, ensuring their long-term operation.
Please clarify what you mean by "Cardiac and respiratory frequencies will also be measured." -Answer: Done. It was corrected in the manuscript, page 8, lines 189 and 190. It now reads: "Heart rate (beats per minute) and respiratory rate (breaths per minute) will also be measured".
Details of how height, weight and abdominal circumference will be measured including instruments to be used should be provided.
-Answer: Done. It was described in page 8, lines 192-207. It reads as follows: "For weight measurement, patient will be asked to stand on the centre of the scale without support, with the arms hanging freely to the sides and with the weight distributed evenly on both feet. A mechanical column scale (SECA 700) with capacity of 220 kg and precision of 0.05 kg will be used and weight will be recorded to the nearest 100 g. Height will be measured with a stadiometer SECA 220, with the subject standing with the feet together and the heels, buttocks and upper part of the back projected in the same vertical plane, with the head oriented in the plane of Frankfurt. Measurement will be taken at the end of a deep inward breath, placing the head board firmly down on the vertex, and recorded to the nearest mm. Waist circumferences will be measured at the level of the narrowest point (or at the mid-point if there is no obvious narrowing) between the lower costal border and the iliac crest by using a measuring tape made of glass fiber Bodyflex, with length of 150 cm and precision of 1 mm. The patient will be instructed to breathe normally and the measurement will be taken at the end of a normal expiration".
Reviewer 2
-Answer: We appreciate your comments. Right now we are not offering monetary or non-monetary incentives to the study participants, other that the benefit of undergoing a clinical and biochemical assessment every two years, which results very attractive for many of our participants. We are focusing on the constant communication with the participants (every 6 months via email, annual phone calls and electronic seasonal postcards), as described in page 6, lines 148-154.
VERSION 2 -REVIEW
REVIEWER
Ambuj Roy AIIMS, New Delhi
REVIEW RETURNED
13-Jun-2017
GENERAL COMMENTS
Thank you for revising the paper.
